INVO Bioscience, Inc.

Equities

INVO

US44984F4019

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 02:00:01 18/07/2024 am IST			5-day change	1st Jan Change
0.8 ^USD	-1.23%		+3.90%	-40.74%

15/05	INVO Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
18/04	Top Premarket Decliners	MT

INVO Bioscience, Inc. announced that it expects to receive $0.015 million in funding

January 22, 2018

INVO Bioscience, Inc. (OTCPK:IVOB) announced that it will raise $1,500,000 in a round of funding on January 22, 2018. The company will issue convertible note ooption pursuant to exemption provided under Regulation D. The minimum investment accepted from any outside investor is $5,000.

Latest news about INVO Bioscience, Inc.

INVO Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	16/05	CI
Top Premarket Decliners	18/04	MT
Sector Update: Health Care Stocks Retreating Late Afternoon	18/04	MT
Top Midday Gainers	17/04	MT
Traders Digest Earnings After Rate-Driven Losses, US Equity Futures Rebound Slightly	17/04	MT
Top Premarket Gainers	17/04	MT
INVO Bioscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	17/04	CI
INVO Bioscience, Inc. announced that it has received $0.5 million in funding from FirstFire Capital Management LLC	08/04	CI
INVO Bioscience, Inc. announced that it expects to receive $0.5 million in funding from FirstFire Capital Management LLC	05/04	CI
Certain Options of INVO Bioscience, Inc. are subject to a Lock-Up Agreement Ending on 9-FEB-2024.	09/02	CI
Certain Warrants of INVO Bioscience, Inc. are subject to a Lock-Up Agreement Ending on 9-FEB-2024.	09/02	CI
Certain Common Stock of INVO Bioscience, Inc. are subject to a Lock-Up Agreement Ending on 9-FEB-2024.	09/02	CI
INVO Bioscience, Inc. announced that it expects to receive $5 million in funding from NAYA Biosciences Inc.	29/12	CI
NAYA Biosciences Inc. Announces Publication of New Data for its CD38-targeted Flex-NK Bispecific Antibody in the American Society of Hematology's Blood Journal	11/12	CI
Top Premarket Gainers	14/11	MT
Earnings Flash (INVO) INVO BIOSCIENCE Reports Q3 Revenue $974,894	14/11	MT
INVO Bioscience, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
Wall Street Set to Open Slightly Higher as Investors Parse Powell Remarks	10/11	MT
Transcript : INVO Bioscience, Inc., NAYA Biosciences Inc. - Special Call	31/23/31
Sector Update: Health Care Stocks Softer Late Afternoon	24/23/24	MT
Sector Update: Health Care Stocks Mixed in Monday Afternoon Trading	23/23/23	MT
INVO Bioscience Shares Skyrocket After Signing Deal to Buy NAYA Biosciences	23/23/23	MT
Wall Street Set to Open Lower Monday as National Activity Index Shows Near-Historic Economic Growth	23/23/23	MT
NAYA Biosciences entered into an agreement to acquire INVO Bioscience, Inc. in a reverse merger transaction for $90.7 million.	23/23/23	CI
Transcript : INVO Bioscience, Inc., Q2 2023 Earnings Call, Aug 14, 2023	15/23/15

Chart INVO Bioscience, Inc.

Duration

Period

More charts

Company Profile

INVO Bioscience, Inc. is a healthcare services fertility company. The Company is focused on expanding the assisted reproductive technology (ART) marketplace by making fertility care accessible and inclusive to people around the world. The Companyâs flagship product is INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the womanâs body. Its treatment solution is the intravaginal culture technique for the incubation of oocytes and sperm during fertilization and early embryo development. Its technique, designated as IVC, provides patients a more connected and intimate experience at a more affordable cost in comparison to in vitro fertilization (IVF), the other advanced ART treatment. Its commercialization strategy is focused on the opening of INVO Centers offering the INVOcell and IVC procedure and the acquisition of existing IVF clinics. The Company operates three INVO Centers in North America.

Sector

Medical Equipment, Supplies & Distribution

Calendar

12/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
INVO BIOSCIENCE, INC.	-40.74%	3.05M
ABBOTT LABORATORIES	-4.90%	182B
MEDTRONIC PLC	-1.36%	104B
DEXCOM, INC.	-7.64%	45.58B
HOYA CORPORATION	+9.30%	46.44B
CENCORA, INC.	+9.63%	44.34B
METTLER-TOLEDO INTERNATIONAL, INC.	+13.63%	29.44B
TERUMO CORPORATION	+20.29%	26.8B
WEST PHARMACEUTICAL SERVICES, INC.	-7.12%	23.82B
STERIS PLC	+4.03%	22.61B

Other Medical Equipment, Supplies & Distribution